• NUKED: Access is everything, with GlyTherix and Telix Pharmaceuticals

  • Sep 10 2024
  • Duración: 30 m
  • Podcast

NUKED: Access is everything, with GlyTherix and Telix Pharmaceuticals

Escúchala gratis

Ver detalles del espectáculo

  • Resumen

  • In early 2023, one of the first two really big radiopharmaceutical drugs ran into a problem. Novartis' prostate cancer therapy Pluvicto, released only the year before, was suddenly in short supply, snarling up just in time treatment schedules.

    In 2024 the supply chain problem is with the isotope Actinium 225, which *everyone* wants for clinical trials. RayzeBio has been a very famous victim, delaying a clinical trial because of the shortages.

    In episode 3 of Nuked we explore where the nukes come from, and how biotechs large and small get their hands on them.

    With GlyTherix CEO Dr Brad Walsh and Telix Pharmaceuticals CEO Dr Chris Behrenbruch, we look at a potential new front in the US-China tariff war, the Russia question, and how an early stage biotech and one with a product in the market organises its nuclear material supplies.

    Support the show
    Más Menos
activate_WEBCRO358_DT_T2
Economía Finanzas Personales Ciencias Biológicas
Más Menos

Lo que los oyentes dicen sobre NUKED: Access is everything, with GlyTherix and Telix Pharmaceuticals

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.

Reseñas de Audible.com

Opiniones de Amazon
No hay comentarios disponibles